McCormick P J, Dimeo A, Neuner E, Artzt K
Cell Differ. 1982 May;11(3):135-40. doi: 10.1016/0045-6039(82)90003-3.
Anti-F9 is a syngeneic antiserum directed against mouse teratocarcinoma cells which also reacts, by complement-mediated cytotoxicity, with early mouse embryos and male germ cells. A molecule (or molecules) which specifically inhibits anti-F9, cytotoxicity can be recovered from the culture medium of undifferentiated teratocarcinoma cells. The inhibitory component is not present in the culture medium of differentiated teratocarcinoma cells or embryonic fibroblasts. The inhibitory material binds to Ricinus communis I affinity columns indicating that it contains terminal non-reducing beta-galactosyl residues. The antigenicity of the molecule does not require protein, since the inhibitory activity is completely protease-resistant. Gel filtration indicates that the protease digested inhibitory material has a molecular weight of more than 80,000.
抗F9是一种同基因抗血清,针对小鼠畸胎瘤细胞,通过补体介导的细胞毒性作用,它也能与早期小鼠胚胎和雄性生殖细胞发生反应。一种能特异性抑制抗F9细胞毒性的分子(或多种分子)可从未分化畸胎瘤细胞的培养基中回收。分化的畸胎瘤细胞或胚胎成纤维细胞的培养基中不存在这种抑制成分。这种抑制性物质能与蓖麻凝集素I亲和柱结合,表明它含有末端非还原性β-半乳糖基残基。该分子的抗原性不需要蛋白质,因为其抑制活性完全抗蛋白酶。凝胶过滤表明,经蛋白酶消化的抑制性物质分子量超过80,000。